The glutamatergic and GABAergic evidence tells a complementary story about excitation-inhibition balance. Enrichment consistently upregulates components of glutamatergic signaling, including AMPA and NMDA receptor subunit expression, alongside enhanced synaptic protein levels and dendritic spine density. Rather than producing runaway excitation, these changes are paired with coordinated adjustments in inhibitory tone, including modifications in GABA synthesis enzymes, vesicular transporters, and the maturation state of interneurons. This paired recalibration is precisely what theories of homeostatic plasticity would predict: when a brain receives sustained increases in afferent stimulation, it does not simply amplify all signals but instead adjusts the gain of excitatory and inhibitory circuits to preserve information processing within functional ranges. The practical consequence is a network that is more responsive to novel input yet less prone to the excitotoxic cascades that follow injury or chronic stress, a combination highly relevant to conditions ranging from epilepsy to stroke recovery.

The cholinergic findings occupy an intermediate position in the evidence hierarchy, with meaningful but less extensive support. Enrichment has been shown to influence acetylcholine release and muscarinic and nicotinic receptor density in hippocampus and cortex, changes that plausibly mediate the attentional and learning enhancements enrichment produces. Given the central role of basal forebrain cholinergic neurons in Alzheimer’s disease pathology, even modest environmental modulation of cholinergic tone carries translational weight. The adrenergic and histaminergic systems, by contrast, have received far less direct investigation in enrichment studies. What evidence exists suggests enrichment alters noradrenergic signaling in ways that interact with stress physiology, since the locus coeruleus-noradrenergic system is a primary conduit between environmental challenge and arousal state. But these findings are often secondary observations rather than the focus of dedicated experiments, which explains their characterization as indirect in the review’s synthesis.

The mechanistic convergence on CREB-dependent transcription and epigenetic remodeling merits particular attention because it suggests a common final pathway through which diverse environmental inputs produce lasting neural change. CREB, the cAMP response element-binding protein, functions as a molecular switch whose phosphorylation state determines whether activity patterns are translated into durable gene expression changes. Enrichment reliably increases CREB phosphorylation in hippocampal neurons, and this activation cascades into the expression of genes governing synaptic structural proteins, neurotrophic factors, and receptor subunits. Epigenetic mechanisms, including histone acetylation and DNA methylation changes at promoters of plasticity-related genes, provide the substrate for these transcriptional shifts to persist. This layered architecture, from receptor-level changes through intracellular signaling to genome regulation, explains why enrichment effects are not merely transient fluctuations in neurotransmitter release but durable reorganizations of circuit function that can outlast the enriched experience itself.

Brain-derived neurotrophic factor deserves specific mention as perhaps the most consistently replicated molecular mediator of enrichment effects. Enrichment robustly increases BDNF expression across hippocampus, cortex, and other regions, and BDNF signaling through its receptor TrkB activates intracellular cascades that intersect directly with both glutamatergic synaptic plasticity and monoaminergic function. The interplay is bidirectional: serotonergic and dopaminergic signaling can themselves regulate BDNF expression, creating feedback loops in which neurotransmitter changes and trophic factor changes reinforce one another. This mutual reinforcement may underlie the observation that enrichment produces effects across multiple domains simultaneously, improving mood, cognition, and stress resilience in parallel rather than sequentially. It also suggests that BDNF could serve as a useful biomarker in future human studies, since peripheral BDNF levels are measurable and correlate with central changes in some contexts, though this correlation remains imperfect and requires careful validation.

The methodological heterogeneity that the review identifies as a limiting factor warrants elaboration, because it shapes how confidently any single finding can be interpreted. Enrichment paradigms vary enormously across laboratories: cage size, the number and identity of enrichment objects, the frequency of object rotation, group housing density, the presence and complexity of running wheels, and the duration of exposure all differ between studies. Some paradigms emphasize sensory novelty, others social complexity, others physical activity, and many combine all three without disentangling their relative contributions. This variability means that when two studies report divergent effects on a given neurotransmitter system, it is often impossible to determine whether the discrepancy reflects true biological differences or simply different operational definitions of enrichment. Standardized reporting of enrichment parameters, analogous to the rigor now expected in reporting genetic constructs or behavioral protocols, would substantially improve the field’s ability to synthesize findings across studies.

The predominance of animal data raises translation questions that deserve honest treatment. Rodent enrichment paradigms, even elaborate ones, cannot fully capture the richness of human environmental experience, and the neural systems they engage may differ in important respects from their human homologs. Nevertheless, several convergent lines of evidence support the relevance of enrichment principles to human health. Epidemiological studies consistently associate educational attainment, occupational complexity, social engagement, and physical activity with reduced dementia risk and better cognitive aging outcomes. Clinical interventions incorporating structured cognitive stimulation, physical exercise, and social interaction have shown measurable benefits in populations ranging from children with neurodevelopmental conditions to older adults with mild cognitive impairment. While these human findings cannot isolate neurotransmitter mechanisms with the precision available in animal work, their consistency with the preclinical literature provides reasonable grounds for cautious optimism about translational potential.

The question of timing, which the review flags as a priority for future research, has particular significance given what is known about developmental sensitive periods. Enrichment during adolescence produces effects on prefrontal cortical development and stress responsiveness that differ qualitatively from enrichment initiated in adulthood, and enrichment in early life can program long-term trajectories of HPA axis function that persist into later stages. Conversely, enrichment initiated in aged animals still produces measurable benefits on neurogenesis and cognition, demonstrating that plasticity is not extinguished with age but rather modified in its magnitude and mechanisms. This lifespan perspective suggests that enrichment is not a single intervention but a family of interventions whose optimal composition depends on the developmental window and the clinical target. A protocol designed to enhance resilience in a healthy adolescent may differ substantially from one intended to slow cognitive decline in an elderly patient with early neurodegeneration.

The therapeutic implications for specific disease categories merit individual consideration. In stroke models, enrichment accelerates functional recovery and promotes peri-infarct plasticity, effects that appear to depend on glutamatergic and BDNF-mediated mechanisms and that have informed rehabilitation approaches emphasizing enriched, task-specific environments over conventional single-skill training. In addiction models, enrichment reduces drug-seeking and relapse-like behavior, likely through normalization of dopaminergic reward circuitry that has been pathologically sensitized by repeated drug exposure. In neurodegenerative disease models, enrichment delays onset and slows progression of pathology in transgenic animals, though whether these effects reflect neurotransmitter modulation, reduced neuroinflammation, enhanced clearance mechanisms, or some combination remains actively investigated. Each of these applications carries distinct translational challenges, but they share the common feature of engaging endogenous plasticity mechanisms rather than introducing exogenous pharmacological agents, which may offer favorable safety profiles if the interventions can be adequately specified and controlled.

The relationship between enrichment and stress physiology provides an additional integrative framework. Enrichment is not simply pleasant stimulation; it involves novelty, complexity, and challenge, elements that activate stress-responsive systems in controlled doses. This controlled activation appears to produce stress inoculation, a phenomenon in which prior manageable challenge enhances subsequent resilience to more severe stressors. The neurochemical signature of this inoculation includes altered glucocorticoid receptor expression, modified serotonergic tone in limbic regions, and enhanced inhibitory control over stress-responsive circuits. Understanding enrichment through this lens reframes it not as the absence of stress but as the presence of optimally calibrated challenge, a distinction with practical implications for designing interventions. Environments that are stimulating but unpredictable in threatening ways may produce different, potentially harmful, outcomes compared to environments that are complex but controllable.

Looking forward, the most productive research directions likely involve combining enrichment paradigms with modern neuroscientific tools that allow cell-type-specific and circuit-level resolution. Single-cell transcriptomics applied to enriched versus standard-housed animals could identify which neuronal populations undergo which transcriptional changes, moving beyond regional averages that obscure cellular heterogeneity. Chemogenetic and optogenetic approaches could test causality by selectively disrupting candidate circuits during enrichment exposure. Longitudinal imaging in animal models could track how enrichment-induced changes unfold over time and whether they persist after enrichment is withdrawn. On the human side, wearable sensing and ecological momentary assessment could quantify real-world environmental complexity in ways that laboratory proxies cannot, enabling more precise characterization of the dose-response relationship between environmental richness and neural outcomes. Advances in non-invasive neurochemistry, including magnetic resonance spectroscopy and emerging PET tracers for specific receptor systems, may eventually allow direct testing of whether the neurotransmitter mechanisms identified in rodents operate similarly in enriched human environments.

The synthesis offered by this review ultimately positions environmental enrichment as more than a laboratory convenience or a welfare improvement for laboratory animals. It represents a naturally occurring, multi-component intervention that engages the brain’s own plasticity machinery across multiple neurotransmitter systems simultaneously, producing coordinated changes that pharmacological approaches targeting single receptors have struggled to achieve. The convergence of evidence across serotonergic, dopaminergic, glutamatergic, and GABAergic systems, unified by common mechanisms of neurotrophic signaling and transcriptional regulation, provides a coherent framework for understanding how environment shapes brain function. Translating this framework into clinical practice will require the methodological standardization, mechanistic dissection, and human validation that the review rightly identifies as priorities, but the foundational evidence now assembled makes this translation a realistic goal rather than a speculative aspiration.

Subject of Research: Environmental enrichment as a multisystem modulator of neurotransmitter function: mechanisms, plasticity, and therapeutic implications

Article Title: Environmental enrichment as a multisystem modulator of neurotransmitter function: mechanisms, plasticity, and therapeutic implications

Article References: Singhal, G., & Baune, B. T. (2026). Environmental enrichment as a multisystem modulator of neurotransmitter function: mechanisms, plasticity, and therapeutic implications. Frontiers in Molecular Neuroscience, 19, Article 1927924. https://doi.org/10.3389/fnmol.2026.1927924

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.1927924

Keywords: environmental enrichment, neurotransmitters, serotonin, dopamine, glutamate, GABA, neuroplasticity, neurogenesis, CREB signaling, mood disorders, neurodegeneration, preclinical research

The research, led by Shuhan Lv and Qian Chen and their colleagues, focused on Olfr544 for a compelling reason. Previous work had shown that this receptor is highly expressed in the cerebral cortex and hippocampus of nine-month-old 5×FAD transgenic mice, a widely used model of Alzheimer’s disease. Its expression localizes near amyloid-beta plaques, the pathological hallmark of the disease, and its mRNA levels fluctuate with both age and disease progression. That pattern alone would be intriguing, but Olfr544 also belongs to a small club of olfactory receptors that have been deorphanized, meaning scientists know their chemical activator. In this case, the trigger is azelaic acid, a naturally occurring dicarboxylic acid that has already been implicated in metabolic regulation elsewhere in the body, including glucagon secretion in pancreatic alpha cells, lipolysis, and mitochondrial biogenesis in skeletal muscle. What remained entirely unknown was the receptor’s function inside the nervous system.

To probe that function, the team turned to the mouse neuroblastoma cell line N2a, a standard workhorse for studying neuronal differentiation and neurite extension. Their first task was to confirm that these cells genuinely possess the machinery for Olfr544 signaling. Using reverse transcription polymerase chain reaction followed by agarose gel electrophoresis and DNA sequencing, they demonstrated that N2a cells endogenously express not just Olfr544 itself but also its canonical downstream partners, the olfactory G protein Gαolf and adenylyl cyclase 3. That trio constitutes the full signaling axis that olfactory receptors use in the nose, and its presence in neuronal cells suggested that Olfr544 could operate as a functional GPCR in the brain rather than sitting there as molecular decoration.

The functional experiments began with azelaic acid. After establishing with an MTT assay that concentrations up to 640 micromolar had no effect on N2a cell viability, the researchers treated serum-deprived cultures with 500 micromolar of the compound for 24 hours. Under phase-contrast microscopy, the effect was unmistakable. Roughly 30 percent of treated cells extended neurites, defined as processes longer than the cell body’s diameter, compared with only about 10 percent of serum-deprived controls. Because short-term serum deprivation itself modestly promotes neurite outgrowth, the azelaic acid effect represented a genuine, receptor-linked enhancement of neuronal differentiation. Direct morphological comparison with receptor-deficient cells proved technically awkward because Olfr544 knockout cells grow and adhere poorly even at baseline, so the team pivoted to a cleaner strategy: dissect the downstream signaling and transcriptional consequences of receptor loss.

Before those genetic experiments, the researchers sought independent confirmation that Olfr544 is sufficient, on its own, to drive CREB-dependent transcription. They cloned the full-length mouse Olfr544 cDNA into a specialized expression vector that promotes proper membrane trafficking of olfactory receptors, then co-transfected it into HEK293T cells, which lack endogenous Olfr544, together with a CREB-responsive dual-luciferase reporter. When azelaic acid was added, luciferase activity surged in receptor-expressing cells but stayed flat in empty-vector controls. Co-treatment with SQ22536, an inhibitor of adenylyl cyclase, markedly blunted the response, confirming that the signal flowed through cAMP production. This heterologous reconstitution ruled out the possibility that azelaic acid’s effects in neuronal cells depend on indirect pathways unique to the N2a environment, and it established a direct mechanistic line from receptor to transcription factor.

The genetic core of the study came from CRISPR-Cas9 editing. The team designed two single-guide RNAs targeting exon 2 of the mouse Olfr544 gene, transfected them into N2a cells, selected edited populations with puromycin, and isolated monoclonal lines by limiting dilution. Sanger sequencing confirmed a homozygous 149-base-pair deletion that introduces a frameshift and a premature stop codon, and reverse transcription PCR showed loss of the wild-type transcript, consistent with nonsense-mediated decay. The authors candidly note that no validated specific antibody existed to confirm receptor loss at the protein level, a limitation they flag explicitly. Still, the functional evidence was decisive. When wild-type N2a cells were stimulated with 50 micromolar azelaic acid for 30 minutes, levels of phosphorylated CREB, the transcription factor that sits at the crossroads of neuronal survival, plasticity, and memory formation, rose significantly. In knockout cells, that increase vanished entirely, while basal pCREB remained unchanged, proving that azelaic acid’s activation of CREB is strictly Olfr544-dependent.

The team then traced the pathway upstream of CREB. Canonical GPCR signaling proceeds through Gαs proteins to activate adenylyl cyclase, elevate intracellular cAMP, and stimulate protein kinase A, which in turn phosphorylates CREB. Enzyme-linked immunosorbent assays showed that azelaic acid triggered a rapid rise in intracellular cAMP in wild-type cells, though a smaller one than forskolin, a direct adenylyl cyclase activator, could produce. In knockout cells, the cAMP response to azelaic acid was completely abolished, and PKA activity followed the same pattern, rising with drug treatment in wild-type cells but not in receptor-deficient ones. Together, these measurements delineate a clean linear cascade: Olfr544 activation, cAMP elevation, PKA activation, CREB phosphorylation. It is the textbook GPCR framework, operating in a neuronal context and converging on a transcription factor that governs synaptic plasticity.

To see what genes this cascade controls, the researchers performed RNA sequencing on wild-type and Olfr544 knockout cells, generating more than 41 gigabytes of clean data with mapping rates between 86 and 95 percent. Differential expression analysis identified 1,727 genes whose expression changed, 1,397 upregulated and 330 downregulated. Enrichment analysis revealed a striking asymmetry. Upregulated genes clustered in the neuroactive ligand-receptor interaction pathway, involving 41 genes encoding GPCRs and ion channels, which the authors interpret as possible compensatory mechanisms. Downregulated genes were concentrated in the motor protein pathway, including members of the myosin, actin, and kinesin families. That downregulation is precisely what one would expect if Olfr544 supports neurite dynamics, because motor proteins are essential for the cytoskeletal remodeling that drives process extension and neuronal morphogenesis. The authors caution that the transcriptomic comparison used a single monoclonal knockout line, so the results should be read as hypothesis-generating candidate pathways rather than a definitive catalog of receptor targets.

From the downregulated genes, computational prediction of CREB binding sites flagged three high-confidence candidates: Igf2bp3, Sorbs2, and Kctd14. Independent validation in the unedited parental cell line strengthened the case, particularly for IGF2BP3, an mRNA-binding protein implicated in axon guidance and synaptic plasticity. Its protein level rose significantly with azelaic acid treatment in wild-type cells and was markedly reduced in knockout cells, with no rescue by the agonist, making it the most robust Olfr544-dependent effector identified. SORBS2, which maintains dendritic complexity and synaptic integrity, and KCTD14, a member of a family linked to neurodevelopmental disorders, showed consistent downward trends in knockout cells, though not every pairwise comparison reached statistical significance. The authors are careful to note that the link between CREB activation and these targets remains correlative and that chromatin immunoprecipitation studies will be needed to confirm direct transcriptional regulation.

The bigger picture is what makes this work resonate beyond the cell culture hood. Olfactory receptors account for roughly 60 percent of human GPCRs, and mounting evidence ties their brain expression to Alzheimer’s disease, Parkinson’s disease, and schizophrenia, with some receptors modulating microglial phagocytosis or tau phosphorylation. This study establishes, for the first time, a direct linear signaling axis connecting a brain-expressed olfactory receptor to the structural machinery of the neuron itself. It also hints at a possible bridge to tau biology, since a homolog of IGF2BP3 binds tau mRNA and IGF2BP3 variants correlate with tau burden in Alzheimer’s patients. The authors are appropriately restrained about the disease connection, emphasizing that their findings are in vitro and that the relevance to Alzheimer’s pathology remains speculative. Future work, they argue, should test Olfr544 in knockout and transgenic mouse models, identify the receptor’s endogenous brain ligands, and determine whether modulating the pathway affects synaptic integrity, neurodegeneration, or cognition. If those experiments pan out, a receptor once thought to exist solely to smell the world may turn out to be a lever for protecting the brain from one of its most devastating diseases.

Subject of Research: The role of the extra-olfactory olfactory receptor Olfr544 in neuronal neurite outgrowth and CREB signaling

Article Title: Role of olfactory receptor Olfr544 in neuronal cells: Insights into neurite outgrowth and CREB signaling

Article References: Lv, S., Liu, J., Zhou, Y., Yang, R., Zhang, T., Deng, Y., Chen, Y., Lai, C., & Chen, Q. (2026). Role of olfactory receptor Olfr544 in neuronal cells: Insights into neurite outgrowth and CREB signaling. iScience, 29(11), Article 117757. https://doi.org/10.1016/j.isci.2026.117757

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117757

Keywords: olfactory receptors, Olfr544, azelaic acid, CREB signaling, neurite outgrowth, N2a cells, cAMP, PKA, CRISPR-Cas9, Alzheimer's disease, GPCR, IGF2BP3

The study, led by Yinliang Zhang, Xiaochen Gai, Dong Zhao and Yongsheng Chang, with contributions from a team at Tianjin Medical University, Capital Medical University and Westlake University, began with a deceptively simple observation. When mice were exposed to cold, or when their fat cells were bathed in norepinephrine, the sympathetic neurotransmitter that surges during cold exposure, levels of ALKBH5 rose sharply in brown and subcutaneous fat. ALKBH5 belongs to a small family of enzymes that remove N6-methyladenosine, or m6A, the most abundant internal chemical modification on messenger RNA. By stripping these methyl marks, ALKBH5 can alter how long particular mRNA molecules survive before being degraded, and therefore how much protein the cell can manufacture from them.

Tracing the signal upstream, the investigators found that ALKBH5 expression is not a passive side effect of cold. Instead, norepinephrine binding to adrenergic receptors triggers the classic thermogenic signaling cascade: cyclic AMP accumulates, protein kinase A is activated, and the transcription factor CREB is phosphorylated and dispatched to the ALKBH5 gene, switching it on. Pharmacological tools confirmed the pathway’s logic. Forskolin and CW 008, which elevate cAMP signaling, boosted ALKBH5 expression in both mouse and human adipocytes, while the CREB inhibitor 666-15 and the PKA inhibitor H89 blunted that induction. In other words, the same sympathetic signal that commands fat cells to burn also instructs them to reprogram their RNA landscape.

The consequences of losing that reprogramming became clear when the team generated mice lacking ALKBH5 specifically in adipose tissue. Both male and female animals showed reduced thermogenic capacity, dropping their body temperature faster during acute cold exposure and dissipating less energy overall. When fed a high-fat diet, the knockout mice gained more weight, accumulated more fat mass and developed impaired glucose homeostasis compared with controls. Crucially, the metabolic defect appeared without changes in food intake or locomotor activity, pointing squarely at energy expenditure rather than appetite as the underlying problem. The findings applied across sexes, strengthening the physiological relevance of the pathway.

The mirror-image experiment proved equally striking. When the researchers delivered an ALKBH5 gene into brown and subcutaneous fat using adeno-associated virus, the treated animals became metabolic overachievers. They maintained higher core body temperatures in the cold, generated greater total energy expenditure, and resisted the weight gain and glucose intolerance induced by a high-fat diet. Human data added a correlative dimension: analysis of gene expression from public cohorts, including the Genotype-Tissue Expression project, showed that ALKBH5 levels in human subcutaneous fat inversely correlate with obesity, suggesting that the mouse findings may translate to human biology.

The deepest insight, however, came from the mechanistic work. Searching for the thermogenic machinery that ALKBH5 controls, the team landed on CKB, creatine kinase B, an enzyme central to the so-called futile creatine cycle. In this circuit, creatine kinase pumps phosphate onto creatine to build phosphocreatine, and a mitochondrial enzyme hydrolyzes it back again, forcing the cell to burn ATP in a loop that generates heat rather than useful work. Deleting ALKBH5 from fat lowered CKB expression and creatine kinase activity, while boosting ALKBH5 raised them. When the researchers depleted creatine with beta-guanidinopropionic acid, the thermogenic benefits of ALKBH5 overexpression largely evaporated, confirming that creatine metabolism is the load-bearing element of the pathway.

Molecularly, the connection between the demethylase and the creatine kinase is an elegant piece of RNA biology. ALKBH5 removes m6A marks from the CKB transcript itself. Those methyl tags, when present, are recognized by YTHDF2, a reader protein that escorts methylated mRNAs to degradation machinery. By demethylating CKB mRNA, ALKBH5 shields it from YTHDF2-mediated destruction, lengthening the transcript’s half-life and allowing more creatine kinase B protein to be produced. Experiments with mutated CKB constructs, methylated RNA immunoprecipitation, and YTHDF2 knockdown in both mouse brown and human beige adipocytes pieced this mechanism together site by site, and the m6A peaks identified on CKB mRNA matched the canonical DRACH sequence motifs predicted from genomic analysis.

Perhaps the most provocative result concerns UCP1, the long-reigning icon of thermogenesis. In mice genetically engineered to lack UCP1 entirely, ALKBH5 overexpression still raised energy expenditure and protected against cold exposure, demonstrating that the creatine-driven pathway operates in parallel with, and independently of, the classical uncoupling mechanism. This echoes recent single-cell studies suggesting that thermogenic fat contains distinct subpopulations of cells, some defined by UCP1 and others by futile cycling enzymes. The new work provides the first known regulatory link between an adrenergic signal and the creatine branch, effectively giving that parallel pathway its own commander.

The therapeutic implications are considerable. Obesity treatments based on increasing energy expenditure have long sought safe ways to activate thermogenic fat, but UCP1-centric strategies face hurdles, including uncertainty about how much functional brown fat adult humans carry and concerns about off-target adrenergic stimulation. A target that works through mRNA stabilization rather than receptor agonism, and that functions even without UCP1, opens a genuinely different door. The authors caution that ALKBH5 is a broad-acting demethylase implicated in diverse processes, from fertility to cancer metabolism to cardiac fibrosis, so any obesity therapy built on it would need careful tissue specificity. Still, the demonstration that a single RNA modification enzyme can rewire cellular fuel chemistry in response to cold reframes thermogenesis as an epitranscriptomic phenomenon, and it hands obesity researchers a new molecular lever precisely where they need it most: the fat that burns.

Subject of Research: The role of the m6A demethylase ALKBH5 in regulating creatine-driven non-shivering thermogenesis in adipose tissue

Article Title: ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold

Article References: Zhang, Y., Du, C., Qiao, W., Qiu, P., Xu, C., Yang, X., Hao, J., Zhao, D., Gai, X., & Chang, Y. (2026). ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold. Nature Metabolism. https://doi.org/10.1038/s42255-026-01592-y

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01592-y

Keywords: ALKBH5, thermogenesis, brown fat, m6A methylation, CKB, creatine kinase, UCP1, obesity, YTHDF2, norepinephrine, CREB signaling, metabolism